Download PDF
Neonatologie Scan 2015; 04(02): 131-148
DOI: 10.1055/s-0034-1392096
Fortbildung
© Georg Thieme Verlag KG Stuttgart · New York

Prävention und Therapie der Retinopathia praematurorum

Isabel Oberacher-Velten
,
Hugo Segerer
Further Information

Publication History

Publication Date:
11 June 2015 (online)

Also available at
    Permissions and Reprints

Einleitung

Nach wie vor zählt die Frühgeborenenretinopathie (Retinopathia praematurorum, RPM) zu den häufigsten Erblindungsursachen in den Industrienationen im Kindesalter. Die neonatologischen Fortschritte haben in den letzten Jahren und Jahrzehnten das Überleben immer unreiferer Frühgeborener ermöglicht. Gleichzeitig hat unser Wissen um Zusammenhänge zwischen der Entwicklung und Progression einer RPM auf der einen und systemischen Parametern auf der anderen Seite enorme Fortschritte gemacht. Gemeinsam sind daher Neonatologen und Augenärzte vor die Aufgabe gestellt, die Prophylaxe und Therapie der RPM mithilfe dieses neu hinzugewonnenen Wissens so gut wie möglich zu optimieren, damit die verbesserten Überlebenschancen nicht mit einem erhöhten Anteil an sehbehinderten Kindern einhergehen.

Der folgende Artikel soll entsprechend dem jetzigen Stand der Literatur einen Überblick sowohl über Möglichkeiten der Prophylaxe der RPM als auch über aktuelle Überlegungen zur Therapie geben.

 

  • Literatur

  • 1 Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci 2000; 41: 1217-1228
    PubMedGoogle Scholar
  • 2 Löfqvist C, Anderson E, Sigurdsson J et al. Longitudinal postnatal weight and Insulin-like Growth Factor I measurements in prediction of Retinopathy of Prematurity. Arch Ophthalmol 2006; 124: 1711-1718
    CrossrefPubMedGoogle Scholar
  • 3 Smith LE. Through the eyes of a child: understanding retinopathy through ROP- the Friedenwald lecture. Invest Ophthalmol Vis Sci 2008; 49: 5177-5182
    CrossrefGoogle Scholar
  • 4 Sonmez K, Drenser K, Capone A et al. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008; 115: 1065-1070
    CrossrefGoogle Scholar
  • 5 Hellström A, Ley D, Hansen-Pupp I et al. New insights into the development of retinopathy of prematurity – importance of early weight gain. Acta Paediatr 2010; 99: 502-508
    CrossrefGoogle Scholar
  • 6 Smith LE, Shen W, Perruzzi C et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularisation by insulin-like growth factor-1 receptor. Nat Med 1999; 5: 1390-1395
    Google Scholar
  • 7 Chen YH, Lien RI, Tsai S et al. Natural history of retinopathy of prematurity: two-year outcomes of a prospective study. Retina 2015; 35: 141-148
    CrossrefPubMedGoogle Scholar
  • 8 Lundgren P, Kistner A, Andersson EM et al. Low birth weight is a risk factor for severe retinopathy of prematurity depending on gestational age. PLoS One 2014; 9: e109460
    CrossrefGoogle Scholar
  • 9 Yau GS, Lee JW, Tam VT et al. Risk factors for retinopathy of prematurity in extremely preterm chinese infants. Medicine (Baltimore) 2014; 93: e314
    CrossrefGoogle Scholar
  • 10 Saugstad OD, Aune D. Optimal Oxygenation of Extremely Low Birth Weight Infants: A Meta-Analysis and Systematic Review of the Oxygen Saturation Target Studies. Neonatology 2014; 105: 55-63
    CrossrefGoogle Scholar
  • 11 Hartnett ME, Lane RH. Effects of oxygen on the development and severity of retinopathy of prematurity. J AAPOS 2013; 17: 229-234
    CrossrefGoogle Scholar
  • 12 Di Fiore JM, Bloom JN, Orge F et al. A higher incidence of intermittent hypoxemic episodes is associated with severe retinopathy of prematurity. J Pediatr 2010; 157: 69-73
    Google Scholar
  • 13 Kaufman DA, Zanelli SA, Gurka MJ et al. Time outside targeted oxygen saturation range and retinopathy of prematurity. Early Hum Dev 2014; 90: 35-40
    Google Scholar
  • 14 Bizzarro MJ, Li FY, Katz K et al. Temporal quantification of oxygen saturation ranges: an effort to reduce hyperoxia in the neonatal intensive care unit. J Perinatol 2014; 34: 33-38
    CrossrefGoogle Scholar
  • 15 McColm JR, Cunningham S, Wade J et al. Hypoxic oxygen fluctuations produce less severe retinopathy than hyperoxic fluctuations in a rat model of retinopathy of prematurity. Pediatr Res 2004; 55: 107-113
    CrossrefPubMedGoogle Scholar
  • 16 Wu C, Löfquist C, Smith LEH et al. for the WINROP Consortium Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants. Arch Ophthalmol 2012; 130: 992-999
    Google Scholar
  • 17 Flückiger S, Bucher HU, Hellström A et al. The early postnatal weight gain as a predictor of retinopathy of prematurity. Klin MonBl Augenheilkd 2011; 228: 306-310
    Article in Thieme ConnectGoogle Scholar
  • 18 Binenbaum G. Algorithms for the prediction of retinopathy of prematurity based on postnatal weight gain. Clin Perinatol 2013; 40: 261-270
    CrossrefGoogle Scholar
  • 19 Sjöström SE, Lundgren P, Öhlund I et al. Low energy intake during the first 4 weeks of life increases the risk for severe retinopathy of prematurity in extremely preterm infants. Arch Dis Child Fetal Neonatol Ed 2015; DOI: 10.1136/archdischild-2014-306816
    Google Scholar
  • 20 Ertl T, Gyarmati J, Gaál V et al. Relationship between hyperglycemia and retinopathy of prematurity in very low birth weight infants. Biol Neonate 2006; 89: 56-59
    CrossrefGoogle Scholar
  • 21 Garg R, Agthe AG, Donohue PK et al. Hyperglycemia and retinopathy of prematurity in very low birth weight infants. J Perinatol 2003; 23: 186-194
    CrossrefPubMedGoogle Scholar
  • 22 Kaempf JW, Kaempf AJ, Wu Y et al. Hyperglycemia, insulin and slower growth velocity may increase the risk of retinopathy of prematurity. J Perinatol 2011; 31: 251-257
    CrossrefGoogle Scholar
  • 23 Raghuveer TS, Bloom BT. A paradigm shift in the prevention of retinopathy of prematurity. Neonatology 2011; 100: 116-129
    CrossrefPubMedGoogle Scholar
  • 24 Dani C, Poggi C, Bresci C et al. Early fresh-frozen plasma transfusion decreases the risk of retinopathy of prematurity. Transfusion 2014; 54: 1002-1007
    CrossrefPubMedGoogle Scholar
  • 25 Rivera JC, Sapieha P, Joyal JS et al. Understanding retinopathy of prematurity: update on pathogenesis. Neonatology 2011; 100: 343-353
    Google Scholar
  • 26 Heidary G, Vanderveen D, Smith LE. Retinopathy of prematurity: current concepts in molecular pathogenesis. Semin Ophthalmol 2009; 24: 77-81
    CrossrefGoogle Scholar
  • 27 Kandasamy Y, Kumar P, Hartley L. The effect of erythropoetin on the severity of retinopathy of prematurity. Eye (Lond) 2014; 28: 814-818
    CrossrefGoogle Scholar
  • 28 Ohlsson A, Aher SM. Early erythropoetin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2014; 26: 4
    Google Scholar
  • 29 Aher SM, Ohlsson A. Late erythropoetin for preventing red blood cell transfusion n preterm and/or low birth weight infants. Cochrane Database Syst Rev 2014; 23: 4
    Google Scholar
  • 30 Weintraub Z, Carmi N, Elouti H et al. The association between stage 3 or higher retinopathy of prematurity and other disorders of prematurity. Can J Ophthalmol 2011; 46: 419-414
    CrossrefGoogle Scholar
  • 31 Hübler A, Knote K, Kauf E et al. Does insulin-like growth factor 1 contribute in red blood cell transfusions to the pathogenesis of retinopathy of prematurity during retinal neovascularization?. Biol Neonate 2006; 89: 92-98
    CrossrefGoogle Scholar
  • 32 Liu PM, Fang PC, Huang CB et al. Risk factors of retinopathy of prematurity in premature infants weighing less than 1600 g. Am J Perinatol 2005; 22: 115-120
    Article in Thieme ConnectGoogle Scholar
  • 33 Casini G, Dal monteM, Fornaciari I et al. The Beta-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases. Progr Retin Eye Res 2014; 42: 103-129
    CrossrefGoogle Scholar
  • 34 Filippi L, Cavallaro G, Bagnoli P et al. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. J Pediatr 2013; 163: 1570-1577
    CrossrefPubMedGoogle Scholar
  • 35 Dal Monte M, Casini G, La Marca G et al. Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Exp Exe Res 2013; 111: 27-35
    Google Scholar
  • 36 Chen J, Joyal JS, Hatton CJ et al. Propranolol inhibition of betaadrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2012; 53: 2968-2977
    CrossrefGoogle Scholar
  • 37 Hard AL, Hellström A. On the use of antiangiogenetic medications for retinopathy of prematurity. Acta Paediatr 2011; 100: 1063-1065
    CrossrefGoogle Scholar
  • 38 Jandeck C, Kellner U, Lorenz B et al. Arbeitsgruppe der Retinologischen Gesellschaft zur Erstellung der Letilinie zur augenärztlichen Screening-Untersuchung von Frühgeborenen. Augenärztliche Screening-Untersuchung von Frühgeborenen. Klin Monatsbl Augenheilkd 2008; 225: 123-130
    Google Scholar
  • 39 Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1988; 106: 471-479
    Google Scholar
  • 40 Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Final results. 15-year outcomes following threshold retinopathy. Arch Ophthalmol 2005; 123: 311-318
    CrossrefGoogle Scholar
  • 41 White JE, Repka MX. Randomized comparison of diode laser photocoagulation verus cryotherapy for threshold retinopathy of prematurity: 3-year outcome. J Pediatr Ophthalmol Strabismus 1997; 34: 83-87
    Google Scholar
  • 42 Paysse EA, Lindsey JL, Coats DK et al. Therapeutic outcomes of cryotherapy versus transpupillary diode laser photocoagulation for threshold retinopathy of prematurity. J AAPOS 1999; 3: 234-240
    Google Scholar
  • 43 Connolly BP, Ng EY, McNamara JA et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome. Ophthalmology 2002; 109: 936-941
    CrossrefPubMedGoogle Scholar
  • 44 Jandeck C, Kellner U, Heimann H et al. Koagulatioinstherapie der Frühgeborenenretinopathie: Vergleich der anatomischen und funktionellen Ergebnisse nach Laser- oder Kryokoagulation. Ophthalmologe 2005; 102: 33-38
    Google Scholar
  • 45 Ng EY, Connolly BP, McNamara JA et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. Ophthalmology 2002; 109: 928-935
    CrossrefGoogle Scholar
  • 46 Capone Jr A, Diaz-Rohena R, Sternberg Jr P et al. Diode-laser photocoagulation for zone 1 threshold retinopathy of prematurity. Am J Ophthalmol 1993; 116: 444-450
    CrossrefGoogle Scholar
  • 47 The Laser ROP Study Group. Laser therapy for retinopathy of prematurity. Arch Ophthalmol 1994; 12: 154-156
    Google Scholar
  • 48 Axer-Siegel R, Maharshak I, Snir M et al. Diode laser treatment of retinopathy of prematurity: anatomical and refractive outcomes. Retina 2008; 28: 839-846
    CrossrefGoogle Scholar
  • 49 Banach MJ, Ferrone PJ, Trese MT. A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity. Ophthalmology 2000; 107: 324-327
    CrossrefGoogle Scholar
  • 50 Fallaha N, Lynn MJ, Aaberg Jr TM et al. Clinical outcome of confluent laser photoablation for retinopathy of prematurity. J AAPOS 2002; 6: 81-85
    CrossrefGoogle Scholar
  • 51 The Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003; 121: 1684-1696
    CrossrefPubMedGoogle Scholar
  • 52 Mintz-Hittner HA, Kennedy KA, Chuang AZ et al. Efficacy of intravitreal Bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364: 603-615
    CrossrefGoogle Scholar
  • 53 Mintz-Hittner HA, Kuffel Jr RR. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008; 28: 831-838
    CrossrefPubMedGoogle Scholar
  • 54 Kusaka S, Shima C, Wada K et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008; 92: 1450-1455
    CrossrefGoogle Scholar
  • 55 Lalwani GA, Berrocal AM, Murray TG et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008; 28: 13-18
    CrossrefGoogle Scholar
  • 56 Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008; 28: 19-25
    CrossrefGoogle Scholar
  • 57 Oberacher-Velten I, Helbig H. VEGF antibodies as therapy for retinopathy of prematurity. Klin Monbl Augenheilkd 2010; 227: 694-700
    Article in Thieme ConnectGoogle Scholar
  • 58 Arevalo JF, Maia M, Flynn Jr HW et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92: 213-216
    CrossrefPubMedGoogle Scholar
  • 59 Hard A-L, Hellström A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review. Acta Paediatr 2011; 100: 1523-1527
    Google Scholar
  • 60 Kong L, Bhatt AR, Demny AB et al. Pharmacokinetics of Bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci 2015; 56: 956-961
    CrossrefPubMedGoogle Scholar
  • 61 Kodjikian L, Souied EH, Mimoun G et al. Ranibizumab versus Bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomizd trial. Ophthalmology 2013; 120: 2300-2309
    CrossrefGoogle Scholar
  • 62 Castellanos MA, Schwartz S, Garcia-Aguirre G et al. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol 2013; 97: 816-819
    CrossrefGoogle Scholar
  • 63 Lin CJ, Chen SN, Hwang JF. Intravitreal ranibizumab as salvage therapy in an extremely low-birth-weight infant with rush type retinopathy of prematurity. Oman J Ophthalmol 2012; 5: 184-186
    CrossrefGoogle Scholar
  • 64 Chen SN, Lian I, Hwang YC et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab. Retina 2015; 35: 667-674
    Google Scholar
  • 65 Barth T, Hufendiek K, Helbig H et al. Laser treatment or intravitreal VEGF inhibition for aggressive posterior retinopathy of prematurity?. Ophthalmologe 2015; [epub ahead of print]
    Google Scholar
  • 66 Stellungnahme von DOG, Retinologischer Gesellschaft und BVA zum Einsatz von Bevacizumab in der Therapie der Frühgeborenenretinopathie. 20. 12. 2011
    Google Scholar